Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



FDA Slams Brakes on Hep-C Drug

It has been a rough five days for Vertex Pharmaceuticals. The FDA placed a partial clinical hold on a key next-generation hepatitis-C drug at the end of last week, and this week's second-quarter earnings were a mixed bag, sending shares lower still.

In this video, health-care analyst David Williamson focuses on VX-135's clinical hold and why investors should be concerned given the drug class' checkered history, but ultimately why it doesn't damage the real reason for owning shares of Vertex.

Rising health care costs continue to be a hotly debated topic, and even legendary investor Warren Buffett called this trend "the tapeworm that's eating at American competitiveness." To learn more about what's happening to the health care system -- and how to potentially profit from this trend -- click here for free, immediate access.

Follow David on Twitter: @MotleyDavid.

Read/Post Comments (1) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On August 02, 2013, at 10:16 AM, pspenland wrote:


    thanks for clarifying the misleading title on your video post.

    but comparing what's been reported by Vertex as reversible elevated liver enzymes (at the 400mg level no less) with serious cardiac events seems to me to be a mistake. particularly, when suitable context is not provided.

    thank you,

    phil penland

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2571371, ~/Articles/ArticleHandler.aspx, 9/26/2016 8:48:05 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 2 days ago Sponsored by:
DOW 18,261.45 -131.01 0.00%
S&P 500 2,164.69 -12.49 0.00%
NASD 5,305.75 -33.78 0.00%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/23/2016 4:00 PM
VRTX $90.63 Down -1.49 +0.00%
Vertex Pharmaceuti… CAPS Rating: ****
GILD $81.37 Down -0.15 +0.00%
Gilead Sciences CAPS Rating: *****